Biotech

15.5K posts

Biotech banner
Biotech

Biotech

@ej23ny

disclaimer: No investment advice and tweets are my opinion or research that I have done. Do your own research before investing in stock market.

Florida, USA Katılım Ağustos 2015
30 Takip Edilen2.9K Takipçiler
Javier
Javier@Javier944712106·
@FeldtInvesting @ej23ny They don’t need to do it conspicuously… You got a bs answer for everything
English
1
0
0
53
Biotech
Biotech@ej23ny·
@Javier944712106 😂 I don’t know why I go back and forth with you. Slow ? RARE recently indicated sense of urgency to conclude the additional analyses Soon as possible.
English
1
0
1
39
Javier
Javier@Javier944712106·
@ej23ny True. Maybe i’m wrong but it looks like they will finish “further analysis on Q2. Meeting with FDA type B meeting on Q3 and file NDA on Q4. Hope i’m wrong but this process looks slow as fuck.
English
1
0
1
36
Biotech
Biotech@ej23ny·
$MREO NO REVERSE STOCK SPLIT MENTION IN PROXY. I WONDER WHY ? 1) I would assume that NDA would be file And stock price would increase $1+ 2026 Annual General Meeting of Mereo BioPharma scheduled for April 7 $ctmx $ALLR $ANTX $EDSA $XBI $CTMX $FEED
Secular Investor@FeldtInvesting

$MREO Annalisa was one of the Rubric appointees. It wouldn’t surprise me if Rubric has already started offloading. They are the last of the whales to still be holding on after setru failure

English
2
0
9
1.5K
Biotech
Biotech@ej23ny·
@FeldtInvesting Whatever. You have answer for everything. Good luck to you
GIF
English
0
0
1
118
Secular Investor
Secular Investor@FeldtInvesting·
@ej23ny Selling smaller amounts does not require immediate filing. Only after material change
English
2
0
0
188
Biotech
Biotech@ej23ny·
@Javier944712106 “further analysis” also means we are not ready to share it with public but we know the data
English
1
0
0
35
Javier
Javier@Javier944712106·
@ej23ny Umm, they said “further analysis” is still ongoing. I did not say this. MREO management and RARE said it in their recent public statements.
English
1
0
2
50
Biotech
Biotech@ej23ny·
$WVE $1.2B Market cap no holla All do respect: poor clinical data on WVE-006, WVE-007: WVE -006 reminder $GSK walked away from cheap licensing deal WVE-007- phase 1 was disappointing What’s left for this company ? Is not worth more than $10
English
0
0
0
363
Biotech
Biotech@ej23ny·
@Javier944712106 😂 your entire tweet doesn’t make sense. 1) analyzing the data doesn’t take more than 4 months. Despite missing the primary end point the data looks 100 times better compared to current standard of care.
English
1
0
0
52
Javier
Javier@Javier944712106·
@ej23ny Getting ahead of urself. They have not even finished analyzing data and then they will have a Type B meeting. This shit will take too much time.
English
1
0
1
75
Biotech
Biotech@ej23ny·
@NextTradeX I have no clue but they until July to do the RS. Unfortunately I don’t have any faith on current CEO. I’m still hopeful
English
1
0
0
26
TaxiBiotech
TaxiBiotech@TaxiBiotech·
@ej23ny @semodough Wait, seriously? I’ve been checking a couple of apps and they’re all saying it’s about 10M. 0.7M OS
English
1
0
0
24
dough
dough@semodough·
$ARTL #Biotech low float Friday pump today 🤷‍♂️🤷‍♂️🤷‍♂️
English
1
0
2
2.5K
Biotech
Biotech@ej23ny·
$EEIQ dirt cheap needs to close above $7.5 for bullish pattern to have chance like $UGRO or $ALTR 1.48M OS $11M market cap $ALTR $UGRO
English
0
0
1
294
Biotech
Biotech@ej23ny·
$GLMD tiny float the stock price should be trading at least $1-$2 not .60 very sad for 6 months short have kept the stock price low Hopefully news is announced soon $INKT $NDRA $ALLR $ANTX $EDSA $XBI $CTMX $UGRO
Biotech@ej23ny

$GLMD ironically similar to $tern originally a metabolic disease company MASH:data was good but the phase 3 suspended do to funding Transitioning into oncology company as well 3-drug combo of Aramchol, Stivarga & Metformin in GI $ctmx $ALLR $ANTX $EDSA $XBI $CTMX $FEED

English
0
0
0
1.1K
Biotech
Biotech@ej23ny·
@ykh6791 They already de listed. The stock is trading otc pink
English
0
0
0
25
Win
Win@ykh6791·
@ej23ny Wouldn't they have appealed to avoid delisting?
English
1
0
0
22
Biotech
Biotech@ej23ny·
$ABP unfortunately got delisted. T-cell engager could have been worth a lot 👇 $Gild is set to acquire Ouro Medicines for up to $2.2 billion, enhancing its portfolio in autoimmune treatments with the promising OM336 T-cell engager.
English
1
0
1
456
Biotech
Biotech@ej23ny·
@stockplaymaker1 $NDRA 1.17M OS tiny float next earnings call is scheduled for March 30, 2026, a potential near-term catalyst as investors look for updates on commercial adoption, partnerships, and regulatory progress
English
3
0
0
354
Stock PlayMaker 🌐
Stock PlayMaker 🌐@stockplaymaker1·
We need a 1000%er. I’m debating to get on X live spaces and start us with a 100%er 🧃
English
11
0
63
6.3K